Purpose Unlimited Inc. Acquires New Position in Charles River Laboratories International, Inc. $CRL

Purpose Unlimited Inc. acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,501 shares of the medical research company’s stock, valued at approximately $698,000.

Other large investors also recently bought and sold shares of the company. Invesco Ltd. increased its holdings in shares of Charles River Laboratories International by 115.8% in the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after acquiring an additional 1,446,972 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new position in Charles River Laboratories International in the fourth quarter worth $176,478,000. Victory Capital Management Inc. increased its stake in Charles River Laboratories International by 9,938.8% during the fourth quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock valued at $137,935,000 after purchasing an additional 684,586 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Charles River Laboratories International by 1,491.1% during the third quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock worth $96,005,000 after purchasing an additional 575,039 shares during the period. Finally, National Bank of Canada FI raised its holdings in shares of Charles River Laboratories International by 117.7% during the third quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock worth $148,131,000 after purchasing an additional 511,901 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 0.1%

Charles River Laboratories International stock opened at $185.17 on Monday. The stock has a market cap of $8.92 billion, a price-to-earnings ratio of -49.25, a PEG ratio of 2.12 and a beta of 1.46. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. The company’s 50-day moving average price is $174.82 and its two-hundred day moving average price is $182.75. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $228.88.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. During the same period in the prior year, the business posted $2.34 EPS. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, analysts expect that Charles River Laboratories International, Inc. will post 11.04 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Morgan Stanley raised shares of Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $185.00 to $220.00 in a report on Wednesday. Robert W. Baird set a $213.00 target price on shares of Charles River Laboratories International in a report on Friday, May 8th. Royal Bank Of Canada initiated coverage on Charles River Laboratories International in a research note on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 target price for the company. Barclays upped their target price on Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Finally, Mizuho set a $192.00 price target on Charles River Laboratories International in a report on Friday, May 8th. Twelve research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Charles River Laboratories International has an average rating of “Moderate Buy” and an average price target of $211.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.